期刊
MULTIPLE SCLEROSIS JOURNAL
卷 23, 期 3, 页码 362-369出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458516672017
关键词
Treatment response; outcome measurement; multiple sclerosis
资金
- Imperial College Healthcare Trust Biomedical Research Centre
- MRC [MR/N026934/1, MC_PC_17114, UKDRI-5003] Funding Source: UKRI
- Medical Research Council [UKDRI-5003, MC_PC_17114, MR/N026934/1, MR/K501013/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0514-10022] Funding Source: researchfish
Treatments with a range of efficacy and risk of adverse events have become available for the management of multiple sclerosis (MS). However, now the heterogeneity of clinical expression and responses to treatment pose major challenges to improving patient care. Selecting and managing the drug best balancing benefit and risk demands a new focus on the individual patient. Personalised medicine for MS is based on improving the precision of diagnosis for each patient in order to capture prognosis and provide an evidence-based framework for predicting treatment response and personalising patient monitoring. It involves development of predictive models involving the integration of clinical and biological data with an understanding of the impact of disease on the lives of individual patients. Here, we provide a brief, selective review of challenges to personalisation of the management of MS and suggest an agenda for stakeholder engagement and research to address them.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据